Abstract
This study evaluates a novel 10% enrofloxacin enteric-coated granule (EEG) formulation designed to improve palatability and therapeutic outcomes in swine. Enrofloxacin (ENR) is highly effective against respiratory pathogens like Actinobacillus pleuropneumoniae (APP) and Mycoplasma suis (MS), but its inherent bitterness often leads to drug refusal. Through pharmacokinetic (PK) analysis, residue depletion studies, and clinical trials, researchers determined that a 5 mg/kg dose administered twice daily for five days provides over 90% clinical efficacy. Furthermore, a safe withdrawal period of five days was established to ensure food safety compliance.
Introduction: Overcoming the Bitterness Barrier
Enrofloxacin is a cornerstone antibiotic in veterinary medicine, particularly for treating severe respiratory infections in pigs. However, its bitter taste presents a significant practical challenge: pigs often refuse medicated feed or water, leading to under-dosing and the potential for antibiotic resistance. To address this, researchers developed enteric-coated granules (EEG) that mask the drug's taste and optimize its release in the intestinal tract.
Methodology and Analytical Validation
The study utilized 171 healthy crossbred pigs and clinical strains of APP and MS. Drug concentrations in plasma and various tissues (liver, kidney, muscle, and fat) were measured using high-performance liquid chromatography (HPLC) with a phosphate buffer and acetonitrile mobile phase.
The analytical method demonstrated high recovery rates (over 84%), meeting the standards of the United States Pharmacopeia (USP). Pharmacokinetic parameters were established following a single 10 mg/kg oral dose, while residue depletion was tracked over five days of repeated 5 mg/kg dosing.
Results and Discussion
In Vitro Antibacterial Activity
Before clinical trials, the EEG formulation was tested against 56 clinical strains of APP. The Minimum Inhibitory Concentration (MIC) distribution showed that the majority of strains were highly sensitive to the drug, with MIC values predominantly falling between 0.03125 and 0.125 µg/ml.
Pharmacokinetics and Residue Depletion
The PK analysis revealed an elimination half-life ($t_{1/2\beta}$) of approximately 15 hours and a peak plasma concentration ($C_{max}$) of 3.38 µg/ml reached at roughly 4 hours ($T_{max}$). This sustained presence in the plasma supports the formulation's efficacy.
Regarding food safety, the residue depletion study found that the drug cleared most quickly from the kidneys and most slowly from the liver. Calculated withdrawal periods for muscle, fat, liver, and kidney were 4.28, 3.81, 4.84, and 3.51 days, respectively.
Clinical Efficacy against APP and MS
In infection models, the 5 mg/kg and 10 mg/kg dosages both achieved over 90% clinical efficacy. These groups showed significant improvements in average daily gain (ADG) and a marked reduction in lung lesion scores compared to untreated controls. The 5 mg/kg dose was identified as the optimal therapeutic level, offering maximum benefit without unnecessary drug use.
Conclusion
The 10% enrofloxacin enteric-coated granules represent a significant advancement in swine medicine. By solving the palatability issue, this formulation ensures reliable dosing and high clinical success against major respiratory pathogens. Based on the residue depletion data, a 5-day withdrawal period is recommended for pigs treated with the optimal 5 mg/kg dose.
Summary updated